EP1559726A3 - Growth differentiation factor-10 - Google Patents

Growth differentiation factor-10 Download PDF

Info

Publication number
EP1559726A3
EP1559726A3 EP04076367A EP04076367A EP1559726A3 EP 1559726 A3 EP1559726 A3 EP 1559726A3 EP 04076367 A EP04076367 A EP 04076367A EP 04076367 A EP04076367 A EP 04076367A EP 1559726 A3 EP1559726 A3 EP 1559726A3
Authority
EP
European Patent Office
Prior art keywords
differentiation factor
growth differentiation
gdf
disclosed
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04076367A
Other languages
German (de)
French (fr)
Other versions
EP1559726A2 (en
Inventor
Se-Jin Lee
Noreen Cunningham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
School of Medicine of Johns Hopkins University
Original Assignee
Johns Hopkins University
School of Medicine of Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University, School of Medicine of Johns Hopkins University filed Critical Johns Hopkins University
Publication of EP1559726A2 publication Critical patent/EP1559726A2/en
Publication of EP1559726A3 publication Critical patent/EP1559726A3/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Growth differentiation factor-10 (GDF-10) is disclosed along with its polynucleotide sequence and amino acid sequence. Also disclosed are diagnostic and therapeutic methods of using the GDF-10 polypeptide and polynucleotide sequences.
EP04076367A 1993-10-08 1994-10-07 Growth differentiation factor-10 Withdrawn EP1559726A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13407893A 1993-10-08 1993-10-08
US134078 1993-10-08
EP94930673A EP0725796A4 (en) 1993-10-08 1994-10-07 Growth differentiation factor-10

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP94930673A Division EP0725796A4 (en) 1993-10-08 1994-10-07 Growth differentiation factor-10

Publications (2)

Publication Number Publication Date
EP1559726A2 EP1559726A2 (en) 2005-08-03
EP1559726A3 true EP1559726A3 (en) 2006-01-25

Family

ID=22461683

Family Applications (2)

Application Number Title Priority Date Filing Date
EP04076367A Withdrawn EP1559726A3 (en) 1993-10-08 1994-10-07 Growth differentiation factor-10
EP94930673A Ceased EP0725796A4 (en) 1993-10-08 1994-10-07 Growth differentiation factor-10

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP94930673A Ceased EP0725796A4 (en) 1993-10-08 1994-10-07 Growth differentiation factor-10

Country Status (5)

Country Link
US (1) US6204047B1 (en)
EP (2) EP1559726A3 (en)
JP (1) JPH09505991A (en)
CA (1) CA2171546A1 (en)
WO (1) WO1995010539A1 (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030617A (en) * 1993-01-12 2000-02-29 The Johns Hopkins University School Of Medicine Use of growth differentiation factor-9 (GDF-9) to inhibit oocyte maturation
US5846770A (en) * 1994-11-22 1998-12-08 Genetics Institute, Inc. DNA molecules encoding human chordin
WO1997035870A1 (en) * 1996-03-26 1997-10-02 Human Genome Sciences, Inc. Growth factor htter36
US6004780A (en) 1996-03-26 1999-12-21 Human Genome Sciences, Inc. Growth factor HTTER36
US5965403A (en) 1996-09-18 1999-10-12 Genetics Institute, Inc. Nucleic acids encoding bone morphogenic protein-16 (BMP-16)
EP2332564A1 (en) 1997-02-07 2011-06-15 Stryker Corporation Matrix-free osteogenic devices, implants and methods thereof
US20010016646A1 (en) 1998-03-20 2001-08-23 David C. Rueger Osteogenic devices and methods of use thereof for repair of endochondral bone, osteochondral and chondral defects
US7041641B2 (en) 1997-03-20 2006-05-09 Stryker Corporation Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects
EP1988395A1 (en) 1997-05-30 2008-11-05 Curis, Inc. Methods for evaluating tissue morphogenesis and morphogenic activity
US20020052026A1 (en) 1997-10-08 2002-05-02 Steven M. Vicik Methods of refolding proteins
US6027917A (en) 1997-12-10 2000-02-22 Genetics Institute, Inc. Bone morphogenetic protein (BMP)-17 and BMP-18 compositions
US7147839B2 (en) 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity
US6727224B1 (en) 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
EP1181041A2 (en) * 1999-04-30 2002-02-27 Curis, Inc. Morphogen-induced enhancement of fertility
US6482936B1 (en) * 2001-04-17 2002-11-19 Pe Corporation (Ny) Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
KR20060133961A (en) 2003-09-12 2006-12-27 와이어쓰 Injectable calcium phosphate solid rods and pastes for delivery of osteogenic proteins
WO2005089829A2 (en) 2004-03-10 2005-09-29 Scil Technology Gmbh Coated implants, their manufacturing and use thereof
CA2563374A1 (en) 2004-04-27 2005-12-08 Research Development Foundation Antagonism of tgf-.beta.superfamily receptor signaling
EP2298335B1 (en) 2004-05-25 2014-09-03 Stryker Corporation Use of OP-1 for treating cartilage defects
US7473678B2 (en) 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
EP1885749B1 (en) * 2005-05-27 2017-08-23 BBS-Bioactive Bone Substitutes Oy Bone morphogenetic protein 3 and osteogenic devices and pharmaceutical products containing thereof
US8147860B2 (en) 2005-12-06 2012-04-03 Etex Corporation Porous calcium phosphate bone material
EP1991282B1 (en) 2006-02-09 2013-06-19 BioMimetic Therapeutics, LLC Compositions and methods for treating bone
AU2007257208B2 (en) 2006-05-17 2013-05-02 Stryker Corporation Use of a soluble morphogenic protein complex for treating cartilage defects
JP5484047B2 (en) 2006-06-30 2014-05-07 バイオミメティック セラピューティクス， エルエルシー PDGF-biomatrix composition and method for treating rotator cuff injury
US9161967B2 (en) 2006-06-30 2015-10-20 Biomimetic Therapeutics, Llc Compositions and methods for treating the vertebral column
US8524265B2 (en) 2006-08-17 2013-09-03 Warsaw Orthopedic, Inc. Medical implant sheets useful for tissue regeneration
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
ES2447516T3 (en) 2006-12-21 2014-03-12 Stryker Corporation Sustained release formulations comprising BMP-7 crystals
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
US8058237B2 (en) 2007-08-07 2011-11-15 Advanced Technologies & Regenerative Medicine, LLC Stable composition of GDF-5 and method of storage
US8741840B2 (en) 2008-02-13 2014-06-03 Washington University BMP-7 for use in treating neointimal hyperplasia
AU2009236459B2 (en) 2008-04-14 2013-07-25 Advanced Technologies And Regenerative Medicine, Llc Liquid buffered GDF-5 formulations
WO2010030714A2 (en) 2008-09-09 2010-03-18 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries
EP2396025A2 (en) 2009-02-12 2011-12-21 Stryker Corporation Peripheral administration of proteins including tgf-beta superfamily members for systemic treatment of disorders and disease
CN102369017A (en) 2009-02-12 2012-03-07 史赛克公司 Compositions and methods for minimally invasive systemic delivery of proteins comprising TGF-beta superfamily members
US20120148539A1 (en) 2009-03-24 2012-06-14 Moulay Hicham Alaoui-Ismaili Methods and Compositions for Tissue Engineering
US8609127B2 (en) 2009-04-03 2013-12-17 Warsaw Orthopedic, Inc. Medical implant with bioactive material and method of making the medical implant
WO2010144696A1 (en) 2009-06-11 2010-12-16 Burnham Institute For Medical Research Directed differentiation of stem cells
US20110224138A1 (en) 2009-09-09 2011-09-15 Julie Krop Methods for treating pain induced by injuries and diseases of an articular joint
US20110224410A1 (en) 2009-09-17 2011-09-15 Hile David Buffers for Controlling the pH of Bone Morphogenetic Proteins
CN102822197A (en) 2009-12-22 2012-12-12 史赛克公司 BMP-7 variants with reduced immunogenicity
NZ601559A (en) 2010-02-22 2014-10-31 Biomimetic Therapeutics Llc Platelet-derived growth factor compositions and methods for the treatment of tendinopathies
US9688735B2 (en) 2010-08-20 2017-06-27 Wyeth Llc Designer osteogenic proteins
CN105198981B (en) 2010-08-20 2019-07-16 惠氏有限责任公司 Osteogenic protein through designing
US10034945B2 (en) 2012-07-13 2018-07-31 Trustees Of Tufts College Silk powder compaction for production of constructs with high mechanical strength and stiffness
WO2017075055A1 (en) 2015-10-26 2017-05-04 President And Fellows Of Harvard College Reduced and oxidized polysaccharides and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994001557A1 (en) * 1992-07-13 1994-01-20 Sumitomo Metal Industries., Ltd. Bone formation-inducing protein

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266683A (en) * 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994001557A1 (en) * 1992-07-13 1994-01-20 Sumitomo Metal Industries., Ltd. Bone formation-inducing protein

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CUNNINGHAM N S ET AL: "Growth/differentiation factor-10: a new member of the transforming growth factor-beta superfamily related to bone morphogenetic protein-3.", GROWTH FACTORS, (1995) 12 (2) 99-109. JOURNAL CODE: AOI. ISSN: 0897-7194., 1995, Switzerland, XP002117268 *

Also Published As

Publication number Publication date
US6204047B1 (en) 2001-03-20
CA2171546A1 (en) 1995-04-20
EP0725796A1 (en) 1996-08-14
WO1995010539A1 (en) 1995-04-20
JPH09505991A (en) 1997-06-17
EP0725796A4 (en) 1999-12-01
EP1559726A2 (en) 2005-08-03

Similar Documents

Publication Publication Date Title
EP1559726A3 (en) Growth differentiation factor-10
CA2194660A1 (en) Growth differentiation factor-11
EP1475440A3 (en) Growth differentiation factor-3
EP1333035A3 (en) Growth differentiation factor-8
WO1995007992A3 (en) Cloned glutamic acid decarboxylase
WO1998021328A3 (en) Human proteins having transmembrane domains and dnas encoding these proteins
AU4528493A (en) In vivo gene therapy with intron-free sequence of interest
EP0759067A4 (en) Transforming growth factor alpha h1
CA2168029A1 (en) Prosaposin and cytokine-derived peptides as therapeutic agents
EP0770089A4 (en) Growth differentiation factor-12
WO1989009787A3 (en) Osteogenic devices
EP1626096A3 (en) In vitro method of detecting a cell proliferative disorder involving fibroblast growth factor homologous factor-1 (FHF-1)
AU9156291A (en) Polypeptide analogs of apolipoprotein e, diagnostic systems and methods using the analogs
AU1366088A (en) Immunosuppressive peptides and methods of use
AU7450887A (en) Novel human TNF polypeptide mutants and DNAs encoding said mutants
AU3460289A (en) Novel protein, sequences containing the gene therefore, vectors, methods of preparation and use
ITMI912432A0 (en) PROCEDURE AND EQUIPMENT FOR THE FERMENTATION OF AMINO ACIDS
CA2137378A1 (en) D-enzyme compositions and methods of their use
AU5168393A (en) Therapeutic and diagnostic methods and compositions based on transducin-like enhancer of split proteins and nucleic acids
AU6428890A (en) Therapeutic peptides and proteins
CA2262465A1 (en) Neuritin, a neurogene
AU1384995A (en) Human circulating cytokine cc-1
WO1998011217A3 (en) HUMAN PROTEINS HAVING SECRETORY SIGNAL SEQUENCES AND DNAs ENCODING THESE PROTEINS
AU1059095A (en) Treatment of viral disease with cd40l peptide
AU5743194A (en) Treatment of dermatological malignancies with biologically active peptides

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 0725796

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

AKX Designation fees paid
REG Reference to a national code

Ref country code: DE

Ref legal event code: 8566

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060726